RESEARCH DOSSIER
Sleep-Wake Disorders and Clinical Sleep Disturbance
Abstract. Sleep-wake disorders are clinically consequential changes in the initiation, maintenance, timing, continuity, breathing-associated organization, or regulation of sleep and wakefulness. This fundamental research monograph examines the historical formation, conceptual classification, physiological and psychological mechanisms, diagnostic methods, experimental evidence, therapeutic interventions, and unresolved problems of clinical sleep disturbance. A critical narrative synthesis integrates the two-process model of sleep regulation, circadian entrainment, the behavioral and cognitive models of chronic insomnia, orexin-mediated state stability, sleep-disordered breathing, and the reciprocal relationship between sleep and psychopathology. Evidence includes original physiological experiments, randomized clinical trials of cognitive behavioral therapy for insomnia, population cohorts, validation studies, professional guidelines, and quantitative evidence reviews. The monograph distinguishes clinical insomnia from insufficient sleep, circadian misalignment, hypersomnolence, parasomnias, and movement or breathing disorders; evaluates self-report versus objective measurement; and critically assesses interventions, adverse effects, reproducibility, age and cultural variation, and digital clinical technologies. It synthesizes previously published scientific research without reporting original experiments or an independently executed systematic review or meta-analysis.
Keywords: sleep-wake disorders; clinical sleep disturbance; chronic insomnia; CBT-I; hypersomnolence; circadian rhythm sleep-wake disorders; sleep apnea; sleepiness; narcolepsy; idiopathic hypersomnia; parasomnias; restless legs syndrome; two-process model; hyperarousal; sleep diaries; actigraphy; polysomnography; sleep restriction; sleep and depression; clinical psychopharmacology; digital CBT-I; Artificial Era
The Clinical Object: Sleep-Wake Disorder and Disturbance
Sleep-wake disorders form a family of conditions in which the capacity to initiate, maintain, time, organize, or regulate sleep and wakefulness is disturbed sufficiently to produce clinically meaningful distress, risk, or functional impairment. Their presentations include difficulty sleeping despite appropriate opportunity, excessive daytime sleepiness despite apparently adequate opportunity, sleep-related respiratory disruption, misalignment between endogenous timing and external schedules, abnormal behaviors arising from sleep, and movement-related phenomena that fragment rest. This clinical definition requires simultaneous attention to nocturnal experience, daytime consequences, timing, available sleep opportunity, relevant medical and psychiatric conditions, and the temporal persistence of symptoms. Sleep complaints can also occur transiently during bereavement, acute illness, environmental disruption, caregiving, examination stress, or shift changes without automatically constituting a persistent disorder. The first scientific task is therefore to define the phenomenon and establish its functional significance rather than to infer a diagnosis from a single symptom Buysse et al. (2006).
The present dossier examines clinical sleep disturbance as a set of interacting psychological, behavioral, circadian, and physiological processes. Its central domain is insomnia, hypersomnolence, circadian sleep-wake disturbance, and their reciprocal association with psychopathology. Sleep apnea, restless legs syndrome, and parasomnias are included because differential diagnosis and comorbidity determine the meaning and safety of psychological formulations. Normal sleep architecture and the general neurobiology of sleep remain fundamental explanatory foundations, but a separate Science research object covers ordinary sleep and circadian regulation. The dossier synthesizes published experiments, validation studies, observational cohorts, clinical trials, systematic evidence assessments, and professional guidelines as a critical narrative scientific review. It presents no original patient data, no preregistered systematic review, and no independent meta-analysis.
Research Questions, Evidence Architecture, and Scope
Five connected research questions structure this monograph. First, how do sleep duration, continuity, timing, architecture, and waking function distinguish clinical phenotypes? Second, which mechanisms explain onset, persistence, and recurrence, including circadian misalignment, sleep homeostasis, learned arousal, cognition, respiratory physiology, and neurological instability? Third, how adequately do sleep diaries, psychometric reports, actigraphy, polysomnography, and physiological testing measure those mechanisms? Fourth, which interventions produce reproducible benefit for which outcomes, over what period, and with which harms? Fifth, what can longitudinal and experimental research establish about bidirectional relationships between disordered sleep and psychiatric symptoms? The comparison of evidence emphasizes the design and population behind each claim: clinical practice guidelines assess broader literatures, trials test intervention packages, observational cohorts establish predictors and trajectories, and laboratory protocols isolate physiological mechanisms Edinger et al. (2021), evidence review Buysse et al. (2006).
Evidence synthesis proceeds by distinguishing conceptual validity, measurement validity, clinical utility, and causal identification. A symptom measure may be reliable but insufficient as a diagnostic instrument; a treatment may improve self-reported insomnia while having smaller or inconsistent effects on objective sleep physiology; a temporal association may reflect shared risk factors or bidirectional feedback rather than a one-way causal chain. For intervention recommendations, the current 2025 VA/DoD insomnia and obstructive sleep apnea guideline provides a particularly useful comparison with AASM guidance published across 2015–2025 VA/DoD (2025) Edinger et al. (2021) Kapur et al. (2017) Winkelman et al. (2025). Historical sources are interpreted in their original conceptual setting: terminology and thresholds have changed, so earlier descriptions cannot simply be mapped onto current classifications without qualification.
Historical Formation of Sleep Medicine and Clinical Sleep Psychology
The scientific history of sleep disorders extends from the description of pathological sleep, somnambulism, and unusual daytime sleepiness to experimental physiology, electrophysiology, circadian science, behavioral treatment, and modern classification. The emergence of electroencephalography made stages and transitions of sleep experimentally observable. Mid-twentieth-century investigation linked waking activation to ascending brain systems; later research identified hypothalamic circuits involved in state stability Saper et al. (2005). Clinical sleep medicine subsequently developed polysomnography, respiratory event measurement, sleep laboratories, and treatment programs that could connect reported symptoms to observed physiological events. This convergence transformed sleep disturbance from a loosely grouped complaint into several testable clinical domains. It also created new questions about the relation between sleep laboratory phenomena and the everyday experience of patients.
Clinical psychology contributed behavioral models that accounted for chronic insomnia even when an acute precipitant had disappeared. In an influential 1987 paper, Spielman, Caruso, and Glovinsky examined conditioning, circadian timing, arousal, and perpetuating factors as connected targets of treatment Spielman et al. (1987). Insomnia research later shifted toward standardized outcomes and established multi-component cognitive behavioral therapy. Ford and Kamerow's population-based 1989 investigation connected sleep complaints with psychiatric diagnoses and suggested a longitudinal relationship warranting prevention research Ford & Kamerow (1989). The Pittsburgh Sleep Quality Index Buysse et al. (1989), Epworth Sleepiness Scale Johns (1991), and Insomnia Severity Index Bastien et al. (2001) subsequently strengthened clinical research by providing distinct measurement lenses. Historical progress here consists in increased differentiation: insomnia and sleepiness, chronic disorder and episodic complaint, schedule misalignment and intrinsic inability to sleep, subjective impairment and physiological events are related but require separate tests.
Classification: Disorders, Phenotypes, and Diagnostic Boundaries
Contemporary diagnostic systems organize sleep-wake disorders by their central dysfunction and characteristic presentation. ICD-11 places sleep-wake disorders within a dedicated chapter and includes insomnia disorders, hypersomnolence disorders, sleep-related breathing disorders, circadian rhythm sleep-wake disorders, sleep-related movement disorders, and parasomnias. The classification is useful because a person who sleeps at the wrong clock time, a person who repeatedly awakens because breathing is obstructed, and a person who is unable to sleep despite favorable circumstances require very different explanatory hypotheses. Classification nevertheless reflects conventions and operational thresholds as well as biological organization. Overlapping syndromes are common; an insomnia presentation may coexist with obstructive sleep apnea, restless legs syndrome, depression, medication effects, or circadian misalignment Kapur et al. (2017) Allen et al. (2014).
The distinction between a symptom and disorder is especially important. Difficulty falling asleep after an unusually late shift can reflect circadian timing, insufficient sleep opportunity, anticipatory stress, or a persistent insomnia disorder. Sleepiness during quiet activity can indicate sleep restriction, untreated apnea, medication effects, central hypersomnolence, or ordinary fluctuations in alertness. Hyperarousal and poor sleep efficiency may accompany multiple conditions and do not uniquely identify a diagnosis. Clinical formulations therefore begin with duration, frequency, opportunity, daytime impairment, chronology, and competing explanations. Diagnostic systems should guide this inquiry without replacing it; the case formulation must preserve information about comorbidities, environment, and behavior that categorical labels alone cannot express Buysse et al. (2006) VA/DoD (2025).
The Two-Process Model and Homeostatic Sleep Pressure
Borbély's 1982 two-process model offered a durable framework for understanding why sleep depends on both elapsed waking time and circadian timing Borbély (1982). In the model, Process S expresses a homeostatic drive that increases with wakefulness and dissipates during sleep; Process C represents the influence of the endogenous circadian oscillator on sleep propensity across the day. Their combined dynamics explain why sleep propensity changes with prior wakefulness and biological time. The model provides an important organizing vocabulary for insomnia, sleep restriction therapy, circadian disturbances, and recovery from insufficient sleep. It is a physiological and mathematical abstraction: it does not by itself diagnose an individual or encompass all effects of stress, illness, breathing disturbance, and cognition.
Dijk and Czeisler tested the contribution of circadian and sleep-homeostatic processes in a controlled human protocol in which eight men followed a scheduled 28-hour rest–activity cycle under temporal isolation, allowing sleep episodes to occur at different internal circadian phases Dijk & Czeisler (1995). The study demonstrated structured interactions among the phase of the circadian pacemaker, sleep propensity, REM sleep, and non-REM electroencephalographic features. A small, tightly controlled mechanistic experiment offers evidence about physiological organization, while its participant number and unusual laboratory conditions limit direct estimation of population prevalence or intervention effectiveness. For clinical interpretation, the crucial consequence is that an individual can have substantial homeostatic sleep pressure at a clock time when the circadian system promotes wakefulness, or relatively low sleep pressure at a socially designated bedtime. Attempts to solve every sleep complaint by extending time in bed can therefore backfire in selected insomnia presentations.
Circadian Pacemakers, Entrainment, and Social Time
Human circadian rhythms are organized around an endogenous timekeeping system synchronized by environmental time cues, especially the timing and intensity of light. Carefully controlled laboratory research has shown that the intrinsic period is close to, but not exactly, 24 hours. In a widely cited 1999 study, Czeisler and colleagues estimated an average intrinsic human circadian period of approximately 24.18 hours under controlled lighting and highlighted the confounding influence of uncontrolled light exposure in earlier estimates Czeisler et al. (1999). Entrainment therefore requires daily alignment with environmental timing; sleep habits, social schedules, and light exposure influence how internal phase maps onto conventional clock time.
Circadian misalignment becomes clinically relevant when endogenous timing and required activity schedules diverge enough to create persistent insomnia symptoms, excessive sleepiness, or functional impairment. A delayed phase can appear to be sleep-onset insomnia if a person is repeatedly required to sleep before their habitual biological night, while an advanced phase can present as unwanted early awakening. Shift work adds occupational constraints, rotating schedules, light exposure during biological night, and restricted recovery opportunity. The AASM 2015 guideline makes clear that intervention research differs across circadian disorder subtypes, ages, light and melatonin regimens, and outcome measures Auger et al. (2015). Biological phase, sleep timing, and perceived fatigue must be recorded separately; they are not interchangeable proxies. A clinical history should investigate workdays and free days, light timing, social obligations, and the opportunity for unconstrained sleep.
Neural Regulation, State Stability, and Arousal
Wakefulness depends on interacting activating systems, while sleep onset involves coordinated changes in neural networks that reduce arousal. A widely used synthesis by Saper, Scammell, and Lu describes hypothalamic mechanisms for switching between sleep and waking states and stabilizing those transitions Saper et al. (2005). Orexin/hypocretin signaling helps sustain waking; its disruption is central to important forms of narcolepsy. These mechanisms help explain why the clinical problem of hypersomnolence involves more than a simple deficit of time asleep. State boundaries can become unstable, producing unexpected sleep episodes, cataplexy, or REM-associated phenomena. Conversely, heightened physiological and cognitive arousal may maintain wakefulness when sleep is desired. Neural mechanisms provide explanatory possibilities that require syndrome-specific evaluation.
Psychophysiological arousal can be studied through electroencephalography, autonomic measures, neuroendocrine indices, behavior, and subjective experience. These measures describe different dimensions and frequently correlate imperfectly. The hyperarousal framework of insomnia, reviewed by Riemann and colleagues, integrates cognitive worry, autonomic activation, sleep-related learning, and broader physiological changes Riemann et al. (2010). Yet elevated average arousal at a group level does not establish a single biomarker suitable for diagnosing every patient. A person may report severe insomnia while demonstrating more total sleep than expected, and another may have measurable sleep disruption without intense worry. A rigorous clinical formulation combines experience, behavior, timing, and physiology while acknowledging the limited specificity of each indicator.
Insomnia Phenomenology and Clinical Course
Insomnia concerns persistent difficulty initiating or maintaining sleep, or waking earlier than desired, accompanied by distress or impairment despite adequate opportunity and circumstances for sleep. Its clinical definition is anchored in the relation between the night and the day. A person may experience a long sleep-onset interval, recurrent nocturnal awakenings, an unwanted terminal awakening, or variable combinations across the week. Daytime consequences include fatigue, attention difficulties, emotional irritability, reduced confidence in performance, and distress about sleep. Sleepiness and fatigue should be distinguished: fatigue is a sense of depleted capacity that may occur without a strong probability of falling asleep. The pattern can fluctuate with work pressure, illness, pain, caregiving, and sleep-related beliefs, so an isolated difficult night cannot establish a chronic insomnia diagnosis Buysse et al. (2006) VA/DoD (2025).
The former distinction between 'primary' and 'secondary' insomnia implied a hierarchy in which insomnia caused by another disorder would necessarily resolve when that disorder was treated. Contemporary clinical thinking increasingly treats insomnia as a potentially independent, reciprocally related condition even when medical or psychiatric problems are present. This is important in chronic pain, mood disorders, and sleep-disordered breathing: the persistence of insomnia may require treatment in its own right. A complete assessment asks when difficulties began, how they evolved, what precipitated episodes, how patients respond during sleepless periods, and which interventions have helped or harmed. Prevalence estimates vary substantially with symptom frequency, duration, impairment criteria, and population sampling; figures should therefore never be transferred across different case definitions as though they measured the same disorder.
Behavioral Conditioning and the Perpetuation of Insomnia
The behavioral account represented by Spielman, Caruso, and Glovinsky emphasizes how factors that originally trigger poor sleep can be replaced by learned patterns that keep it going Spielman et al. (1987). An illness, breakup, or demanding work period may initiate acute insomnia. A person may then extend time in bed, begin going to bed unusually early, sleep late when possible, nap unpredictably, repeatedly check the clock, or remain in bed struggling to sleep. Some adaptations reduce immediate anxiety but weaken the association between bed and sleep or lower consolidated sleep pressure at the intended bedtime. The result is a self-reinforcing pattern, even after the initial stressor diminishes. The formulation is probabilistic and individualized; it does not make every sleep habit pathological or imply that the patient chose the disorder.
Stimulus control seeks to rebuild an association between the sleep environment and sleep rather than protracted wakefulness and frustration. Sleep restriction or sleep compression seeks to consolidate sleep by calibrating time in bed to estimated actual sleep, with later adjustment based on response. Such procedures target identifiable behavioral mechanisms but can temporarily increase sleepiness; appropriate screening and clinical monitoring matter when patients drive, work in hazardous settings, have seizure disorders, bipolar disorder, a history of falls, or other significant safety concerns. These techniques are not interchangeable with the generic instruction to 'get better sleep hygiene.' The AASM guideline conditionally supports individual components and strongly supports multi-component cognitive behavioral therapy for chronic insomnia Edinger et al. (2021).
Cognitive Models: Worry, Monitoring, and Safety Behavior
Harvey's cognitive model proposes that negatively biased thought about insufficient sleep, vigilance for evidence of impaired performance, and counterproductive safety behaviors help maintain chronic insomnia Harvey (2002). Anticipatory thoughts such as 'tomorrow will be a disaster' may increase emotional and physiological activation at bedtime. The person may monitor bodily sensations, the clock, noise, or perceived wakefulness with unusual intensity; attention to sleep difficulty amplifies threat appraisal and frustration. During the day, fatigue and ordinary lapses may be attributed exclusively to poor sleep, strengthening the expectation of further failure. The model integrates cognition with arousal and behavior, but its precise sequence must be tested rather than assumed to hold identically for every patient.
Clinical assessment benefits from differentiating realistic concern from exaggerated prediction, and from identifying whether sleep-related safety strategies produce short-term comfort at a long-term cost. Cognitive work addresses beliefs about absolute sleep requirements, catastrophic interpretations of waking, excessive performance monitoring, and the expectation that sleep must be forced. Behavioral experiments can test predictions and promote flexible responses. The model also explains why self-reported sleep quality, sleep satisfaction, and objective sleep variables can diverge: appraisal and attention contribute to the lived experience without making that experience unreal. Psychometric scales quantify distress and perceived impairment, while diaries and physiological recording permit comparisons across distinct constructs Bastien et al. (2001) Buysse et al. (2006).
Hyperarousal: Psychological and Physiological Accounts
The hyperarousal model proposes that increased activation may involve cognitive-emotional processes, autonomic physiology, cortical activity, and longer-term stress regulation Riemann et al. (2010). Its appeal comes from the observation that people with insomnia often describe feeling tired while remaining unable to disengage from vigilance or thought. Hyperarousal can be operationalized through several measures, including presleep worry, physiological activation, and electrophysiological features, but findings differ across samples and techniques. There is no single validated biological signature that explains all clinical insomnia. A model that predicts average group differences is not automatically a sensitive or specific clinical test. The major methodological challenge is to determine which arousal dimensions precede insomnia, which arise as consequences, and which jointly reflect another process.
The model overlaps with conditioning and cognitive accounts without replacing them. Worry about wakefulness can increase arousal; arousal makes sleep more difficult; learned expectations can turn the bed into a cue for alertness. Yet persistent insomnia can also occur with low reported anxiety, medical complications, sleep-related breathing disorders, or circadian scheduling problems. An integrative clinical explanation therefore tests competing mechanisms in a particular history. Treatments targeting arousal, cognition, sleep timing, and conditioning may work through several pathways at once. This is why improvement after therapy cannot, by itself, establish which single mechanism caused the disorder.
Insomnia Measurement: Diaries, ISI, PSQI, and Clinical Interview
Research quality depends on matching the measurement to the construct. A prospective sleep diary records bedtime, intended sleep time, estimated sleep-onset latency, perceived time awake after sleep onset, final awakening, arising time, naps, and perceived quality. From these data investigators can calculate estimated total sleep time, time in bed, and sleep efficiency, while recognizing that such estimates express perception and recall under a structured procedure rather than directly observed physiology. The 2006 standard-assessment recommendations of Buysse and colleagues emphasized defined case criteria, qualitative and quantitative sleep assessment, waking outcomes, and documentation of comorbidities Buysse et al. (2006). The interview remains important because a weekly average can conceal alternating workday restriction and free-day recovery.
The Pittsburgh Sleep Quality Index evaluates multiple dimensions of self-reported sleep quality and disturbance over a month Buysse et al. (1989). The Insomnia Severity Index quantifies perceived insomnia symptoms, satisfaction, interference, and distress, with validation for research assessment and change measurement Bastien et al. (2001). Their utility depends on the language and population in which they are used, acceptable missingness, and whether score changes reflect clinically meaningful benefit. Neither instrument replaces clinical diagnosis or measures obstructive respiratory events. The Epworth Sleepiness Scale concerns likelihood of dozing across situations and is informative about a different construct Johns (1991). Combining scores indiscriminately under one 'sleep severity' index would obscure mechanistically different problems and may reduce validity.
Cognitive Behavioral Therapy for Insomnia: Components and Evidence
Multi-component cognitive behavioral therapy for insomnia (CBT-I) combines sleep-focused behavioral scheduling, stimulus control, cognitive restructuring or appraisal work, sleep education, and often relaxation or techniques for reducing presleep activation. Its procedures are individually adapted rather than rigidly identical for every patient. Edinger and colleagues' 2021 AASM guideline strongly recommends multi-component CBT-I for chronic insomnia disorder in adults and provides conditional recommendations for some single-component procedures Edinger et al. (2021). An accompanying systematic review evaluated randomized controlled trials, critical sleep outcomes, and the certainty of supporting evidence using GRADE methods Edinger et al. (2021), evidence review. The conclusion is specific: psychotherapy with sleep-focused behavioral methods has an established evidence base for chronic insomnia and occupies a central position in professional recommendations.
The randomized trial by Morin and colleagues compared CBT alone, CBT combined with medication, and longer-term treatment strategies for persistent insomnia Morin et al. (2009). Its importance lies in distinguishing initial benefit from maintenance of improvement, rather than presuming that the intervention producing the fastest early symptom change must yield the best long-term result. Such trials require attention to selection criteria, treatment fidelity, participant expectations, attrition, and the definition of remission. The 2025 VA/DoD guidance likewise recommends CBT-I and favors it over medication as first-line treatment, with briefer behavioral treatment supported for selected cases VA/DoD (2025). Sleep hygiene education alone has consistently weaker guideline support than structured CBT-I; advice about light, caffeine, and bedtime regularity may supplement treatment but should not be equated with a complete evidence-based therapeutic protocol.
Digital CBT-I, Access, Durability, and Equity
Digital delivery offers a scalable route to insomnia treatment, including structured self-guided lessons, diaries, tailored scheduling, and interactive behavioral feedback. Digital CBT-I should be evaluated as a clinical intervention with a defined therapeutic content, not as a generic sleep app or collection of relaxation recordings. The OASIS randomized trial assigned 3,755 university students reporting insomnia to digital CBT for insomnia or usual care and found improvements in insomnia and several psychological outcomes Freeman et al. (2017). A separate randomized clinical trial involving 1,711 participants reported benefits in insomnia symptoms, functional health, well-being, and sleep-related quality of life after digital CBT-I Espie et al. (2019). Those studies provide useful evidence about treatment efficacy and potential scalability while leaving questions about uptake, completion, accessibility, diverse patient populations, and sustained engagement.
Real-world comparisons require more caution than randomized treatment trials. The 2023 observational study by Lu and colleagues compared digital CBT-I and medication-based care in a large clinical dataset but explicitly identified instability of some findings Lu et al. (2023). Such designs can identify patterns relevant to implementation, yet treatment choice, illness complexity, motivation, affordability, and differential follow-up may confound observed outcomes. A useful translational agenda therefore measures who begins treatment, who completes its components, how co-occurring apnea or psychiatric illness is screened, whether digital prompts encourage risky unsupervised sleep restriction, and which adaptations maintain fidelity. Data privacy and unequal digital access also influence the real clinical reach of behavioral sleep care.
Circadian Sleep-Wake Disorders and Their Distinct Clinical Logic
Circadian sleep-wake disorders arise when the timing of the internal circadian system, its entrainment, or the relation between internal biological time and external demands produces persistent symptoms and functional consequences. Delayed and advanced sleep-wake phase patterns concern the placement of a relatively consolidated sleep episode; irregular sleep-wake rhythm involves fragmented distribution of sleep across the 24-hour day; non-24-hour rhythm involves systematic drift relative to clock time; shift work and jet lag types concern externally imposed misalignment. The clinical logic is temporal. A person who sleeps well when permitted to follow a habitual delayed schedule may differ substantially from someone with sleep-onset insomnia at every attempted bedtime. Accurate diagnostic assessment therefore requires chronology, sleep timing, free-day behavior, and the extent to which symptoms change when schedule restrictions are removed Auger et al. (2015).
Sleep logs and actigraphy can help characterize day-to-day regularity, phase patterns, and variation under competing schedules, while objective circadian phase markers are useful in some specialized assessments. Interventions seek to modify phase, strengthen rhythmic signals, or adapt social schedules to biological constraints. Light and melatonin are timing-sensitive signals, and a change in dose, timing, environment, or individual sensitivity can alter the effect. The 2015 AASM guideline evaluated evidence separately for delayed, advanced, irregular, and non-24-hour disorders rather than assuming one universal protocol Auger et al. (2015). Clinical recommendations must account for age, eye disease, psychiatric vulnerability, medication, pregnancy, and the practical possibility of consistent timing. Mechanistic findings about circadian entrainment are strong, but optimal clinical implementation remains more heterogeneous.
Delayed and Advanced Sleep-Wake Phase: Developmental and Behavioral Context
Delayed sleep-wake phase disorder is characterized by persistent timing of the main sleep episode later than desired or socially required, often producing difficulty falling asleep at a conventional bedtime and waking for morning commitments. The diagnosis depends on a stable or recurrent phase pattern and associated impairment, rather than on an isolated late bedtime or a culturally disapproved preference. In some adolescents and young adults, physiological developmental changes in circadian timing intersect with evening light exposure, school start times, and social activity. A clinician needs to determine whether the person obtains adequate, satisfactory sleep when allowed to follow the preferred schedule. This distinction can reduce inappropriate labeling of circadian misalignment as generalized inability to sleep Auger et al. (2015).
Advanced sleep-wake phase disorder produces an opposite timing difficulty, with a propensity for early evening sleep and unwanted early awakening. The relevant impairment may be inability to participate in evening obligations or maintain desired social schedules. Neither phase condition is adequately evaluated with a single sleep quality score, since total duration may be normal when circadian preferences are respected. Behavioral scheduling, environmental light timing, and chronobiological interventions must be considered in relation to internal phase; applying the same bright light schedule indiscriminately could move rhythms in the wrong direction. The evidence base for subtypes and age groups differs, so practical recommendations should remain anchored in the actual guideline population and the patient's functioning rather than extrapolated from general chronobiology.
Shift Work, Jet Lag, and the Organization of Social Time
Shift work imposes a mismatch between biological night and occupational activity, often involving exposure to artificial light during night hours and an attempt to sleep when circadian wake promotion is strong. These demands may result in curtailed or fragmented daytime sleep, substantial work-time sleepiness, and variable recovery on days off. Diagnosis requires an association with the work schedule and its consequences, while a comprehensive evaluation considers insufficient opportunity, household obligations, transportation, comorbid insomnia, apnea, and substance use. Jet lag likewise reflects temporary misalignment after rapid travel across time zones, with direction, magnitude of shift, and exposure to local light influencing adaptation. In both conditions, the experience of fatigue may be shared, while the underlying time course and intervention strategy differ.
A clinical and occupational perspective adds considerations beyond the individual symptom. Night driving, patient care, industrial machinery, and long shifts turn sleepiness into a public safety issue. Human scheduling systems can increase exposure to circadian misalignment; health outcomes cannot be interpreted solely as failures of personal discipline. Longitudinal observational studies of shift workers are vulnerable to healthy-worker selection, socioeconomic confounding, and differences in work rotation. Controlled interventions can test light, schedule design, alertness support, and education, but may not reproduce the social demands of real workplaces. Evidence-based practice therefore integrates biological timing with organizational constraints and the feasibility of sustained change Czeisler et al. (1999) Auger et al. (2015).
Irregular and Non-24-Hour Sleep-Wake Rhythms
Irregular sleep-wake rhythm disorder involves poorly consolidated sleep across day and night, with multiple episodes instead of a stable major sleep period. It is particularly relevant when neurological illness, impaired environmental time cues, reduced physical activity, or care arrangements affect behavioral and circadian consolidation. Its assessment depends on recording the distribution of sleep over repeated days rather than relying on the patient to identify one bedtime. The disorder must be distinguished from ordinary fragmentation due to caregiving, nocturnal symptoms, environmental interruption, or a chosen polyphasic schedule. Treatment studies have examined structured activities, time cues, light, and environmental design, but results vary with underlying neurocognitive and social conditions Auger et al. (2015).
Non-24-hour sleep-wake rhythm disorder involves recurrent drift of sleep timing relative to the external 24-hour day; it is particularly important in some totally blind people who cannot use conventional retinal photic entrainment. Periods of apparently satisfactory alignment may alternate with episodes of severe insomnia or daytime sleepiness as internal phase moves through social time. Longitudinal diaries and actigraphy are crucial for recognizing such patterns, which a short assessment can miss. The intrinsic human circadian period measured by Czeisler and colleagues establishes the biological possibility of progressive drift when entrainment is absent Czeisler et al. (1999). Yet individual diagnosis requires actual temporal records and differential evaluation. Pharmacologic entrainment strategies and light-based treatment, where biologically relevant, warrant specialist assessment of indication and safety.
Hypersomnolence: Sleepiness, Fatigue, and Inadequate Opportunity
Excessive daytime sleepiness is an increased propensity to fall asleep in situations where wakefulness is expected. It differs from fatigue, subjective low energy, low motivation, and cognitive slowing, although patients may report these experiences together. The differential diagnosis begins with insufficient sleep opportunity or chronic restriction, irregular schedules, sleep-disordered breathing, sedating medications, depression, neurological illness, and central disorders of hypersomnolence. Because several conditions can coexist, confirmation of adequate prior sleep and a careful chronology are central to interpreting specialized tests. A patient who experiences prolonged sleep episodes or sudden irresistible sleep attacks requires a different hypothesis than someone who feels exhausted but remains consistently awake Johns (1991) Krahn et al. (2021).
The Epworth Sleepiness Scale permits standardized description of situations in which dozing is likely, while objective laboratory assessments address other components of physiological sleep propensity Johns (1991). In the Multiple Sleep Latency Test, controlled opportunities to fall asleep are used in the evaluation of certain central disorders. In the Maintenance of Wakefulness Test, the focus is the capacity to remain awake in a quiet setting. Krahn and colleagues' 2021 protocol guidance emphasizes sleep schedule documentation, preparation, medication and substance effects, and standardized conditions because these can change test outcomes Krahn et al. (2021). Scores should be interpreted alongside symptoms, clinical records, and physiological context. No single questionnaire, latency value, or home wearable provides a complete diagnosis.
Narcolepsy, Orexin, Cataplexy, and State Boundary Instability
Narcolepsy is a central disorder of hypersomnolence characterized by persistent sleepiness and, in some patients, cataplexy and REM-associated phenomena. The history of orexin/hypocretin research transformed its mechanistic understanding. Lin and colleagues identified a mutation affecting an orexin receptor in a canine narcolepsy model in 1999 Lin et al. (1999). Thannickal and colleagues subsequently documented a reduction in hypocretin-containing neurons in human narcolepsy tissue Thannickal et al. (2000). These studies connect a clinical disorder with identifiable state-stabilizing systems and illustrate how convergent animal genetics and human neuropathology can inform pathophysiology. Their findings should not be generalized to every individual with daytime sleepiness or to all clinical narcolepsy subtypes.
Clinical evaluation considers cataplexy, sleep paralysis, hallucinations around sleep transitions, nighttime sleep instability, and potential alternative causes of daytime symptoms. Standardized sleep testing and, in selected contexts, biomarkers aid classification. Treatment evidence concerns wake-promoting agents, symptom-directed therapies, structured schedules, and safety planning. The AASM 2021 guideline for central disorders of hypersomnolence reviews available treatments across narcolepsy and related conditions, with recommendations dependent on diagnosis and population Maski et al. (2021). Clinical significance includes the ability to study, work, drive, maintain relationships, and manage stigma. Some subjective impairment persists even when pharmacological treatment improves measured wakefulness, so patient-centered outcomes must supplement laboratory measures.
Idiopathic Hypersomnia and Complex Diagnostic Uncertainty
Idiopathic hypersomnia presents persistent excessive sleepiness that is not adequately explained by insufficient sleep, circadian misalignment, other sleep disorders, medical conditions, or medications. Some patients report prolonged sleep duration, severe difficulty awakening, and sleep inertia, although manifestations vary. The diagnostic challenge is substantial because reported daytime impairment, objective sleep propensity, sleep duration, and symptom history do not always align. Repeated sleep recordings and careful assessment of prior habitual sleep may be more informative than a single short laboratory session. Diagnostic boundaries with narcolepsy and insufficient sleep syndrome remain a topic of scientific debate; mechanisms are incompletely established Krahn et al. (2021) Maski et al. (2021).
A sound research program distinguishes the stability of a clinical phenotype from the validity of any proposed biological explanation. An unvalidated biomarker can produce attractive mechanistic stories without adequate sensitivity or specificity. Intervention studies are often smaller or more heterogeneous than those available for common insomnia, making certainty of comparative benefit more limited. For each treatment claim, the evidence appraisal should record whether the trial enrolled patients with well-defined idiopathic hypersomnia, used a reliable comparator, followed symptoms beyond initial response, and captured adverse outcomes. The management objective extends beyond fewer unplanned naps: it involves sustained daytime participation, alertness under ordinary demands, and predictable functioning.
Sleep-Disordered Breathing and the Psychological Meaning of Fragmented Sleep
Sleep-related breathing disorders can interrupt respiration and fragment sleep, producing daytime sleepiness, fatigue, cognitive complaints, and mood changes that superficially resemble insomnia or psychiatric conditions. Obstructive sleep apnea involves recurrent upper-airway obstruction during sleep, with associated physiological events that require appropriate objective assessment. Clinical clues can include habitual snoring, witnessed pauses in breathing, gasping, hypertension, morning symptoms, and daytime impairment, but their presence or absence alone does not establish or exclude the disorder. The AASM 2017 diagnostic guideline distinguishes in-laboratory polysomnography from home sleep apnea testing and identifies circumstances in which a negative, inconclusive, or technically inadequate home test should be followed by laboratory evaluation Kapur et al. (2017).
Psychological research asks how respiratory events interact with perceived sleep quality, distress, attention, and treatment adherence. An individual can have both obstructive sleep apnea and chronic insomnia; treating the respiratory component may improve awakenings but not necessarily resolve learned wakefulness or anxiety associated with bed. The 2025 VA/DoD guideline explicitly addresses insomnia and obstructive apnea in the same management framework VA/DoD (2025). Prevalence must be reported with severity thresholds, age, sex, body habitus, and sampling context. The Wisconsin Sleep Cohort research analyzed by Peppard and colleagues illustrates how obesity and historical changes in population characteristics alter estimates of sleep-disordered breathing Peppard et al. (2013).
Positive Airway Pressure, Adherence, and Person-Centered Outcomes
Positive airway pressure (PAP) reduces upper-airway obstruction during sleep and is an established treatment approach for appropriate adults with obstructive sleep apnea. AASM recommendations on PAP emphasize treatment effectiveness and practices supporting adherence Patil et al. (2019). NICE guidance provides another jurisdictional example of decisions based on symptoms, severity, quality-of-life impact, and associated considerations NICE (2021). These recommendations concern medical treatment of sleep-disordered breathing and should be distinguished from psychological therapy for insomnia. Their outcomes can include sleepiness, quality of life, and physiological event measures, each of which may respond differently. The clinical goal is improved functioning and risk management rather than a favorable device statistic alone.
Treatment adherence involves practical and psychological processes: discomfort, fit, nasal symptoms, expectations, anxiety, stigma, domestic arrangements, and the perceived benefit of nightly use. Education and troubleshooting may improve implementation, but causal claims about particular adherence strategies require controlled evidence. A person with co-occurring insomnia may struggle to use a mask while awake and distressed, making coordinated care relevant. Follow-up should evaluate residual sleepiness, persistent insomnia, possible treatment-related problems, and the accuracy of initial diagnosis. Untreated apnea should also be considered before labeling a patient with primary insomnia, recommending sedating medications, or conducting tests for central hypersomnolence Kapur et al. (2017) VA/DoD (2025).
Restless Legs Syndrome, Periodic Movements, and Sensory-Motor Sleep Disruption
Restless legs syndrome (RLS) involves an urge to move the legs, typically associated with uncomfortable sensations that begin or worsen during inactivity, improve at least partly with movement, and are more prominent in the evening or night. Diagnostic evaluation must distinguish RLS from leg cramps, positional discomfort, neuropathic symptoms, arthritis, and habitual restlessness. The International Restless Legs Syndrome Study Group updated consensus diagnostic criteria in 2014 to improve specificity and clinical discrimination Allen et al. (2014). RLS may delay sleep onset, fragment sleep, and contribute to mood or daytime complaints, yet it is a distinct syndrome with sensory-motor characteristics. Periodic limb movements observed during sleep are physiological events; their presence does not automatically establish periodic limb movement disorder or identify the cause of insomnia.
The 2025 AASM guideline places significant emphasis on evaluating iron status, addressing exacerbating factors, and selecting interventions according to actual indications Winkelman et al. (2025). It recommends several alpha-2-delta ligand treatments for adults with RLS and revises the place of older dopaminergic approaches because long-term worsening or augmentation is clinically important. Iron-related interventions require appropriate clinical testing and review of contraindications; laboratory thresholds should not be treated as a universal self-medication instruction. In research, patient-reported symptoms, sleep continuity, limb movement indices, and quality of life are separate endpoints. Clinical improvement in one dimension does not guarantee equivalent improvement in another.
Parasomnias: NREM Arousal Disorders and Differential Diagnosis
Parasomnias involve unwanted events around sleep onset, during sleep, or during the transition to wakefulness. NREM arousal disorders include sleepwalking and sleep terrors, typically involving incomplete arousal from NREM sleep. Clinical histories should document timing, recall, stereotypy, complexity of behavior, injury risk, family history, precipitating sleep deprivation, alcohol or medication use, and possible coexisting sleep apnea. Nocturnal epileptic seizures, panic attacks, dissociative episodes, and substance-related behaviors can resemble parasomnia and require careful differential evaluation. The distinction matters because a behavioral episode's appearance alone cannot securely identify its sleep stage or cause.
Environmental safety is essential when episodes include wandering, falls, exits from the home, or threatening behavior. Intervention research is limited by episodic frequency, spontaneous developmental remission, variation in definitions, and the ethical difficulty of experimentally provoking dangerous events. Sleep regularity and treatment of contributing conditions may be relevant; medication decisions require an individualized clinical evaluation. Diagnoses of adult-onset or atypical parasomnia may justify video-polysomnography when indicated to distinguish REM- and NREM-related mechanisms or epileptic events. Psychological interpretations should be proportionate to the available physiological and historical evidence.
REM Sleep Behavior Disorder and Neurodegenerative Significance
REM sleep behavior disorder (RBD) is characterized by dream-enactment behavior associated with loss of normal REM sleep muscle atonia, with potential injury to the patient or bed partner. This syndrome has major clinical significance because it can occur in association with neurological disease and may precede some synucleinopathies in selected populations. However, a probabilistic association at the group level does not justify deterministic predictions for an individual patient. Distinguishing RBD from other parasomnias, obstructive apnea with arousal behavior, nocturnal seizures, and medication-related phenomena requires careful clinical assessment and often video-polysomnography. The AASM clinical practice guideline published in 2023 addresses idiopathic, secondary, and medication-associated RBD and emphasizes safe sleep environments Howell et al. (2023).
The evidence for symptomatic intervention should be understood alongside the limitations of trial populations and the necessity of injury prevention. Physical safety practices do not depend on proving a single neurodegenerative explanation; they address the immediate danger of complex nocturnal movements. Medication selection may depend on age, cognition, comorbid respiratory disease, fall risk, and other conditions. Clinical conversations about prognosis must avoid converting population risk into an individual diagnosis, particularly when the evidence comes from specialized referral cohorts rather than community sampling. The research frontier includes biomarkers of progression, longitudinal phenotyping, early neurological changes, and the consequences of diagnosis for quality of life.
Insufficient Sleep Syndrome, Sleep Debt, and Experimental Restriction
Chronic insufficient sleep opportunity can produce marked impairment while leaving the physiological capacity to sleep intact. People may voluntarily or structurally curtail time in bed because of employment, study, caregiving, commuting, housing conditions, or digital activity, sometimes compensating with longer sleep on free days. The diagnosis and interpretation of insufficient sleep require a realistic assessment of opportunity, regularity, behavior, and the recovery pattern. Distinguishing this condition from insomnia is crucial: a person who cannot obtain sufficient rest because the schedule excludes sleep has a different clinical problem than someone awake for long periods despite an adequate opportunity.
Experimental work by Van Dongen and colleagues randomized 48 healthy adults to 4, 6, or 8 hours of time in bed across 14 nights and compared sustained restriction with total sleep deprivation Van Dongen et al. (2003). The investigators observed cumulative, dose-dependent deficits in waking neurobehavioral performance under restricted sleep opportunity. They also found that subjective sleepiness did not fully track the continuing accumulation of deficits. This laboratory design supports causal inference about short-term dose effects in monitored healthy adults, while it does not directly determine long-term disease risk in every population. The result matters for education and occupational policy: perceived adaptation to short sleep may coexist with deteriorating performance. Clinical advice must also consider the safety of sleepiness when patients drive or perform hazardous work.
Sleep Pharmacotherapy, Prescribing Boundaries, and Safety
Pharmacotherapy for insomnia is heterogeneous: agents differ in targets, duration of action, indications, adverse effects, interactions, and regulatory status. The AASM 2017 pharmacologic guideline evaluated individual medications rather than assuming that all hypnotics have a common benefit-risk profile Sateia et al. (2017). The 2025 VA/DoD guideline generally favors CBT-I first and provides treatment-specific conditional recommendations, reflecting ongoing evaluation of effectiveness and harms VA/DoD (2025). Sedative medications may interact with alcohol, opioids, other depressants, respiratory conditions, age-related vulnerabilities, and fall risk. A medication's regulatory approval for adult insomnia does not imply that it is the first-line option for every patient, or that it treats co-occurring apnea, circadian misalignment, or other primary disorders.
Drug-specific warnings are central to clinical safety. The U.S. Food and Drug Administration announced in 2019 a boxed warning for complex sleep behaviors associated with eszopiclone, zaleplon, and zolpidem, including rare serious injuries and deaths FDA (2019). Orexin receptor antagonists offer a different pharmacological mechanism, but their official labeling includes precautions about daytime impairment, mood symptoms, complex sleep behaviors, and contraindications relevant to narcolepsy DailyMed (2026). Medication selection, monitoring, tapering, withdrawal effects, and changing regulatory information belong to clinical prescribing practice. This monograph evaluates classes and evidence conceptually and does not give patient-specific doses, self-treatment plans, or advice to change prescribed drugs independently.
Insomnia, Depression, and Longitudinal Psychiatric Risk
Insomnia and depression often coexist, but their relationship is more informative when studied prospectively than when measured at a single interview. Ford and Kamerow's 1989 epidemiologic study provided early evidence that sleep disturbance can precede subsequent psychiatric problems Ford & Kamerow (1989). Baglioni and colleagues' 2011 meta-analysis of longitudinal epidemiological research found that insomnia was associated with an elevated subsequent risk of depression Baglioni et al. (2011). Such findings make insomnia a candidate risk marker and potential intervention target. They do not establish that every case of depression is caused by sleeplessness: baseline mood symptoms, pain, medications, socioeconomic adversity, and common liabilities may influence both endpoints. Cohorts differ in whether insomnia means symptoms, standardized questionnaire thresholds, or a clinically assessed disorder, and those definitions matter when comparing risk estimates.
Depression can disrupt sleep timing, sleep initiation, sleep continuity, and early morning awakening, while changes in motivation, activity, and daytime light exposure may further destabilize sleep. Conversely, persistent insomnia can intensify emotional distress, undermine concentration, and complicate psychological recovery. This pattern supports integrated assessment rather than relegating sleep symptoms to a secondary footnote. Clinical intervention trials that directly treat insomnia can examine subsequent depressive outcomes, but improvement in symptoms during therapy should be distinguished from a demonstrated reduction in incident depressive disorder. A stronger causal research design would measure sleep and mood repeatedly, monitor treatments and shared confounders, and establish whether changes in the sleep process temporally mediate changes in depression.
Anxiety, Trauma, Nightmares, and Threat Monitoring
Anxiety disorders and trauma-related conditions may involve difficulty settling at bedtime, hypervigilance, recurrent awakenings, distressing dreams, and avoidance of sleep. The cognitive mechanisms proposed by Harvey Harvey (2002) help explain why expectation, worry, and selective attention to threat can maintain insomnia even when the original stressor has changed. In trauma-related presentations, nightmares and fear associated with sleep can become additional drivers of nighttime avoidance. Yet nightmares, insomnia, and daytime hyperarousal represent separable clinical targets; an intervention effective for one may not address the others. A comprehensive assessment therefore distinguishes the content and timing of distressing dreams, sleep schedule, safety behavior, comorbid conditions, and the effect of medication or alcohol.
The relationship is potentially reciprocal. Anxious arousal can interfere with sleep, while insufficient or fragmented sleep can heighten emotional reactivity and undermine coping. Evidence from observational studies must be differentiated from experimental tests, which may establish the short-term effect of sleep loss on selected emotional outcomes without proving chronic disease causation. Effective treatment planning follows the actual clinical presentation and may involve trauma-focused care, sleep-focused behavioral treatment, or coordinated attention to nightmares and comorbid sleep apnea. The question for longitudinal research is whether treating one system changes the course of the other, in which populations, and through what measured process. Generalized assumptions about all trauma survivors are inappropriate because heterogeneity in symptoms, exposure, supports, and recovery is substantial.
Bipolar Disorder, Social Rhythms, and Mood Instability
Sleep and circadian organization have special clinical relevance to bipolar disorder because changes in sleep need, sleep duration, daily scheduling, and activity can accompany shifts in mood states. A person with reduced need for sleep in an elevated mood episode may have an experience different from insomnia with persistent tiredness and unsuccessful attempts to rest. Harvey's integrative review considered sleep and circadian rhythms as candidate mechanisms and treatment-relevant processes in bipolar disorder Harvey (2008). These mechanisms require careful temporal study: disturbance may occur before, during, or after an episode, and medication or lifestyle changes can alter the observed pattern. Reduced sleep should be evaluated in relation to mood, energy, goal-directed activity, and safety rather than treated as an isolated behavioral variable.
Interpersonal and social rhythm therapy addresses regularity of social activities and daily rhythms in addition to interpersonal processes. Frank and colleagues reported randomized evidence on two-year outcomes in patients with bipolar I disorder Frank et al. (2005). The trial is important because it locates circadian consistency within an explicit psychosocial intervention rather than assuming that the biological clock can be controlled by simple sleep advice. Still, trial eligibility and intervention components complicate attribution of benefit to a single timing mechanism. Aggressive sleep restriction undertaken without specialist assessment can be particularly concerning when bipolar instability is present; a sleep intervention that temporarily increases sleep loss must be considered in the wider psychiatric risk context. Strong clinical integration monitors sleep timing, mood, alertness, and adverse effects together.
Psychosis, Unusual Experiences, and Experimental Sleep Treatment
Sleep difficulties have been studied in relation to paranoia, unusual perceptual experiences, and psychosis-related distress. Cross-sectional association does not by itself distinguish whether insomnia contributes to psychological symptoms, arises as a consequence, or shares causes with them. The OASIS study provides unusually informative evidence: Freeman and colleagues randomized university students with insomnia to digital cognitive behavioral treatment or usual care and measured changes in insomnia and mental health outcomes Freeman et al. (2017). Improvements in insomnia were accompanied by smaller benefits in several psychiatric symptom measures, and mediation analyses examined whether improved sleep explained some changes. The design supports a causal effect of offering the intervention on measured outcomes within that sample.
The interpretation still requires precision. OASIS recruited students, not a representative cohort of people with established schizophrenia-spectrum disorders, and psychotic-like experiences measured by questionnaires are not interchangeable with clinically diagnosed psychosis. Mediation analysis relies on assumptions that are stronger than the original randomized treatment comparison, including the absence of unmeasured mediator-outcome confounding. Nevertheless, the study supports treating sleep as an active domain of mental-health research rather than a passive correlate. Future trials should investigate clinical psychosis populations, repeated within-person measurement, adverse effects, functional outcomes, and how improvements in sleep interact with antipsychotic treatment, stress, and social support.
Childhood, Adolescence, Perinatal Life, and Aging
Clinical sleep evaluation must be developmentally situated. Children and adolescents differ from adults in sleep requirements, circadian timing, school and family constraints, typical parasomnias, and the interpretability of laboratory tests. Daytime behavioral or attentional difficulties can coexist with inadequate opportunity or fragmented sleep and should not be attributed automatically to one underlying psychiatric disorder. The AASM's 2024 pediatric testing guidance describes preparation and interpretation of multiple sleep latency testing with explicit attention to age-related needs, medication and substance effects, sleep-disordered breathing, and delayed sleep phase Maski et al. (2024). Sleep diaries, caregiver reports, school-day patterns, and standardized tests have different strengths, and a method validated in adults may require distinct pediatric evidence.
The perinatal period also changes sleep opportunity, continuity, emotional demands, and vulnerability to clinical symptoms. Palagini and colleagues' 2023 systematic review and meta-analysis included 34 studies involving 835,021 perinatal women and reported associations between insomnia symptoms and maternal mental-health outcomes Palagini et al. (2023). Such pooled estimates must be considered alongside the designs and heterogeneity of included studies and the possibility of confounding by pain, mood, social context, and obstetric factors. In later life, medical illness, nocturia, pain, polypharmacy, neurocognitive changes, and altered schedules complicate the interpretation of insomnia and sleepiness. Evaluation must distinguish age-related changes in sleep organization from clinically meaningful disturbance, assess fall and medication risks, and respect patient priorities.
Sleep Disturbance and Suicidality: Evidence and Safety
Sleep disturbance has been investigated as a risk factor for suicidal thoughts and behaviors. Harris and colleagues' 2020 meta-analysis synthesized longitudinal studies and reported that sleep-related problems can predict subsequent suicidality at a group level Harris et al. (2020). This prospective orientation is an advance on purely simultaneous correlation, but it does not imply a specific deterministic outcome for an individual. Definitions of insomnia, nightmares, suicidal ideation, attempts, and follow-up vary across studies; some designs may incompletely adjust for depression, trauma, substance use, chronic pain, or acute stress. Risk prediction and causal explanation are separate scientific tasks, and effect sizes in a population cannot replace a direct clinical assessment of current safety.
Clinical evaluation of sleep disturbance should therefore take serious accompanying distress and safety signals into account while maintaining a comprehensive view of the person's psychiatric and social circumstances. Sleep complaints can coexist with hopelessness, agitation, exposure to traumatic experiences, or medication changes that require specialized care. A treatment that improves an insomnia score has not automatically been shown to prevent suicidal behavior. Trials designed to examine that outcome need appropriate power, rigorous safety monitoring, and ethically robust response procedures. The scientific conclusion is that sleep assessment contributes useful clinical information and can identify a potentially treatable dimension, while suicide risk assessment follows established clinical protocols independent of any single sleep measure.
Occupational, Cultural, and Structural Determinants of Sleep Disturbance
Sleep opportunity is distributed through social and economic arrangements. Night work, long shifts, multiple jobs, housing conditions, neighborhood noise, caregiving, unstable schedules, educational demands, and access to safe sleeping environments all influence when and how long people can rest. These exposures affect measurement: self-reported 'insomnia' may partly indicate enforced short sleep, chronic circadian misalignment, or fragmented opportunity. A clinical framework that treats every reduced sleep duration as a failure of individual self-regulation would misclassify structural causes. Laboratory evidence on cumulative neurobehavioral effects of restricted sleep Van Dongen et al. (2003) reinforces the importance of distinguishing the biological cost of lost rest from the question of who can realistically obtain adequate opportunity.
Cultural context influences expectations about bedtime, napping, household sleeping arrangements, and thresholds for reporting distress. Research must ensure that symptom translations and instruments preserve construct validity across languages and populations. Occupational surveillance and workplace interventions should evaluate safety events, performance, perceived sleepiness, shift rotation, and recovery time without assuming that an association between one schedule and an outcome is unconfounded. Implementation science also asks which communities can access behavioral sleep treatment, specialist testing, or PAP devices, and which barriers persist after treatment is recommended. Equity in sleep care therefore concerns the distribution of time, infrastructure, trustworthy assessment, and intervention resources as well as the efficacy of treatment itself.
Polysomnography, Actigraphy, Wearables, and Construct Validity
Polysomnography combines physiological channels to characterize sleep stages, respiratory events, leg movements, heart activity, and related signals in a controlled setting. It is especially important when clinical history suggests sleep apnea, atypical parasomnia, certain movement disorders, or central hypersomnolence testing. For ordinary chronic insomnia without indicators of another disorder, routine polysomnography is generally not the default diagnostic tool: history, validated questionnaires, and sleep records often address the relevant clinical questions Kapur et al. (2017) VA/DoD (2025). A laboratory night can be affected by unfamiliar surroundings, scheduling, and the fact that the patient's habitual pattern may not be reproduced. Physiological measurement offers high specificity for some processes but cannot replace direct assessment of lived distress and everyday impairment.
Actigraphy uses movement patterns to estimate rest–activity timing over multiple days and is especially valuable for irregular schedules, circadian phase presentations, and corroboration of sleep diary trends. Its limitation is conceptual: quiet wakefulness may be classified as sleep, and movement is an indirect marker rather than electrophysiological sleep itself. Consumer wearables may add heart-rate or optical measures, yet accuracy depends on algorithm, device version, population, and condition. A device's apparent precision should be validated against an appropriate reference standard and across relevant patient groups. For every research result, investigators should specify recording nights, device settings, missing data, scoring thresholds, and whether the endpoint represents perceived or measured sleep.
Research Designs for Causes, Consequences, and Feedback
Evidence linking sleep-wake disturbance to health outcomes comes from several complementary designs. Laboratory sleep deprivation isolates short-term manipulation of sleep opportunity and establishes causal effects on selected measures under controlled conditions Van Dongen et al. (2003). Cross-sectional surveys estimate contemporaneous associations, but cannot resolve directionality. Prospective cohorts can show that baseline insomnia predicts later outcomes while remaining vulnerable to shared risk factors and measurement errors Baglioni et al. (2011). Randomized clinical trials can estimate the effect of treatment assignment on measured symptoms and functioning, though treatment packages often affect several mechanisms simultaneously Morin et al. (2009) Freeman et al. (2017). Physiological experiments such as circadian desynchrony studies help identify processes under unusual laboratory constraints Dijk & Czeisler (1995).
An integrative account should link specific scientific claims to the strongest relevant design. Experimental sleep loss can establish that restriction impairs vigilance in a defined setting; it cannot, by itself, tell us that chronic insomnia caused a later mood disorder in a community sample. A prospective association can support risk forecasting, but may not establish that adjusting one sleep variable alone will prevent illness. A mediation analysis following randomized CBT-I can test a proposed pathway, but its causal interpretation relies on additional assumptions beyond random treatment assignment. Triangulation across methods becomes most informative when predicted effects, temporal ordering, and observed heterogeneity are specified before analysis.
Treatment Outcomes, Effectiveness, Comparative Benefit, and Harm
Clinical sleep trials may report sleep-onset latency, time awake after sleep onset, sleep efficiency, total sleep time, insomnia severity, remission, sleepiness, patient satisfaction, work functioning, and adverse events. A treatment's effectiveness cannot be reduced to one favorable number because different outcomes have different clinical importance. For example, an intervention may reduce distress and preoccupation more than it increases objectively measured sleep duration, while a therapy for obstructive apnea may improve respiratory indices without eliminating an independent insomnia disorder. Guidelines synthesize outcomes using explicit judgments about certainty and benefit–harm tradeoffs, but recommendations differ in population, context, comparator, and the date of evidence review Edinger et al. (2021), evidence review Sateia et al. (2017) VA/DoD (2025).
Interpretation also requires follow-up duration. An intervention that produces short-term symptom relief may differ from one that maintains benefit after structured treatment ends; a medication that reduces sleep latency can still produce next-day impairment or other harms. Comparator conditions matter: waitlist, usual care, attention control, and another active treatment do not estimate the same contrast. Attrition, selective outcome reporting, expectancy, unblinded assessment, and the representativeness of enrolled patients shape effect estimates. For nonpharmacological therapy, fidelity and therapist expertise matter; for digital interventions, completion and algorithmic delivery influence real-world outcomes. A comparative treatment claim is strongest when it identifies a population, outcome, timeframe, design, and the principal known harms.
Evidence Limitations: Heterogeneity, Reproducibility, and Diagnostic Drift
Sleep-wake studies often use divergent definitions of insomnia, sufficient opportunity, sleep quality, fatigue, daytime sleepiness, and remission. Some samples rely on one questionnaire item, while others apply a structured clinical interview and duration or impairment criteria. Pooling such populations without careful subgroup analysis can create misleading average estimates. Laboratory studies may select healthy participants without common comorbidities; treatment trials may exclude severe mental illness, substance misuse, unstable medical disease, or safety-critical jobs. The resulting estimates can be internally credible yet difficult to generalize to clinical care. Changes in diagnostic criteria over time also complicate historical comparisons, and publication bias can favor promising findings in small studies.
Reproducibility depends on transparent protocol reporting, pre-specified outcomes, standardized definitions, accessible instruments, and careful documentation of analytic choices. Independent replication is particularly important for proposed physiological signatures of hyperarousal and for digital therapies whose software can change during follow-up. A statistically significant group difference is insufficient for an individual diagnostic test if sensitivity, specificity, and measurement reliability are poor. Similarly, consistency of a questionnaire score is not equivalent to physiological confirmation. This monograph's own synthesis is narrative: it prioritizes verified scholarly and guideline sources but does not reproduce an exhaustive database search, risk-of-bias table, formal GRADE review, or meta-analytic pooling. Those tasks remain distinct research activities.
Clinical Integration and Differential Formulation
Clinically useful evaluation starts with a chronology: the sleep complaint, its duration, the opportunity available for sleep, work and family scheduling, objective and reported sleep patterns, daytime consequences, and possible medical or psychiatric contributors. Depending on presentation, assessment may include a sleep diary, insomnia severity scale, daytime sleepiness scale, actigraphy, respiratory testing, or specialist physiological measurements. The purpose is to separate competing mechanisms while preserving comorbidity. Insomnia can occur with apnea; delayed sleep phase can coexist with anxiety about early obligations; medications can change alertness independently of sleep quality. A coherent formulation identifies what each measure can establish and what would count as disconfirming evidence Buysse et al. (2006) Kapur et al. (2017) Krahn et al. (2021).
Treatment reasoning similarly distinguishes intervention targets. Structured CBT-I addresses chronic insomnia mechanisms; circadian interventions address phase and entrainment; PAP addresses upper-airway obstruction; RLS interventions address sensory-motor symptoms and associated mechanisms; central hypersomnolence requires specialized evaluation; trauma-related nightmares may require additional interventions. These approaches are informed by different bodies of evidence and have distinct safety considerations Edinger et al. (2021) Auger et al. (2015) Patil et al. (2019) Winkelman et al. (2025) Maski et al. (2021). Coordination becomes especially important when a patient has bipolar vulnerability, possible suicidal ideation, hazardous driving demands, or sedative medication exposure. An evidence-oriented model tests clinically plausible explanations and follows meaningful outcomes rather than imposing a single universal sleep treatment.
Artificial Era, Digital Sleep Interventions, and the Limits of Inference
In the Artificial Era, sleep-wake research increasingly encounters digital behavioral interventions, passive sensors, predictive analytics, and conversational systems that help people record routines or navigate treatment programs. These technologies can expand the temporal resolution of research, reduce certain access barriers, and create new ways to study the relation between perception and behavior. The randomized OASIS and digital CBT-I studies demonstrate that structured software-delivered behavioral interventions can produce meaningful clinical outcomes within defined populations Freeman et al. (2017) Espie et al. (2019). The evidence concerns specified treatment programs and measured human outcomes, rather than a general claim that artificial systems possess a human sleep need or an equivalent internal physiology.
Scientific evaluation of sleep technologies should distinguish sensor validity, treatment efficacy, user adherence, personalization, privacy, and the possibility of harmful feedback. A wearable that repeatedly labels a person as a poor sleeper may alter vigilance or anxiety even if the underlying physiological estimate is uncertain. A predictive model trained on a specific population may perform poorly for shift workers, older adults, or people with neurological conditions. Artificial-agent guidance requires validated escalation for potential apnea, dangerous sleepiness, psychiatric destabilization, or serious adverse reactions; automation should make the evidentiary provenance of claims inspectable. Philosophical accounts of Artificial Sapiens belong to a separate theoretical plane. In this dossier, Artificial-era propositions remain research questions about human–artificial interaction, technology governance, and empirically measured sleep outcomes.
Future Research: Personalized Sleep Mechanisms and Longitudinal Causality
One central research priority is to identify mechanistically meaningful subgroups that can be assessed reliably before treatment. Insomnia phenotypes might differ in sleep timing, perceived versus objectively recorded wakefulness, cognitive worry, physiological arousal, coexisting apnea, and mood vulnerability, but a proposed subgroup becomes useful only when it predicts outcome, course, or treatment response in independent datasets. Prospective studies with repeated daily measures can examine whether changes in worry precede awakening, whether shifts in circadian timing precede psychiatric deterioration, and how occupational constraints modify these relationships. Longitudinal analyses require careful control of stable and time-varying confounding and should report missing-data mechanisms.
Further priorities include culturally validated measurement, access to CBT-I, prevention among workers with constrained sleep opportunity, comparative digital treatment with durable follow-up, and the long-term benefit–harm profiles of medications. Clinical trials should measure meaningful daytime functioning and safety, rather than sleep efficiency alone, and should include populations commonly excluded from efficacy studies when ethically appropriate. Research on narcolepsy, idiopathic hypersomnia, RBD, and other less common syndromes benefits from multicenter recruitment and transparent biomarker evaluation. Digital tools should be tested prospectively against clinically relevant endpoints, with independent validation and explicit standards for algorithmic updates. Evidence quality will improve when disorder definition, physiological measurement, patient-reported outcomes, and clinical decision context are aligned.
Conclusion
Sleep-wake disorders constitute a diverse but connected field of clinical psychological and physiological investigation. Their scientific unity lies in the study of how sleep opportunity, internal timing, state regulation, learned associations, thought, emotion, respiratory physiology, neurological mechanisms, and social organization shape nocturnal rest and waking function. The two-process model explains basic timing dynamics; cognitive and behavioral models clarify important mechanisms of chronic insomnia; controlled deprivation studies demonstrate consequences of restricted opportunity; specialized sleep testing differentiates disorders for which symptom descriptions alone are insufficient. The clinical meaning of a symptom emerges from its chronology, opportunity, functional impact, and differential explanation.
The strongest treatment evidence in chronic insomnia supports structured multi-component CBT-I, while circadian disorders, obstructive apnea, sensory-motor disturbances, parasomnias, and central hypersomnolence require disorder-specific evaluation and interventions. Longitudinal and experimental research links sleep disturbances with depression, anxiety, unusual experiences, and safety-related outcomes, but causal interpretation depends on design, timing, confounding, and intervention specificity. This critical narrative synthesis establishes a research architecture for integrating mechanisms, measurement, treatment evidence, and human social context. Its guiding principle is that clinical sleep science advances through precise diagnostic boundaries, valid measurement, independent replication, and outcomes that matter to people in their actual environments. A research program for the Artificial Era adds rigorous evaluation of digital interventions and human–artificial sleep technologies without confusing technical possibility with demonstrated clinical benefit.
References
- Allen, R. P., Picchietti, D. L., Garcia-Borreguero, D., Ondo, W. G., Walters, A. S., Winkelman, J. W., Zucconi, M., Ferri, R., Trenkwalder, C., & Lee, H. B. (2014). Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: Updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria—history, rationale, description, and significance. Sleep Medicine, 15(8), 860–873. https://doi.org/10.1016/j.sleep.2014.03.025
- Auger, R. R., Burgess, H. J., Emens, J. S., Deriy, L. V., Thomas, S. M., & Sharkey, K. M. (2015). Clinical practice guideline for the treatment of intrinsic circadian rhythm sleep-wake disorders: Advanced sleep-wake phase disorder, delayed sleep-wake phase disorder, non-24-hour sleep-wake rhythm disorder, and irregular sleep-wake rhythm disorder. Journal of Clinical Sleep Medicine, 11(10), 1199–1236. https://doi.org/10.5664/jcsm.5100
- Baglioni, C., Battagliese, G., Feige, B., Spiegelhalder, K., Nissen, C., Voderholzer, U., Lombardo, C., & Riemann, D. (2011). Insomnia as a predictor of depression: A meta-analytic evaluation of longitudinal epidemiological studies. Journal of Affective Disorders, 135(1–3), 10–19. https://doi.org/10.1016/j.jad.2011.01.011
- Bastien, C. H., Vallières, A., & Morin, C. M. (2001). Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Medicine, 2(4), 297–307. https://doi.org/10.1016/S1389-9457(00)00065-4
- Borbély, A. A. (1982). A two process model of sleep regulation. Human Neurobiology, 1(3), 195–204. https://pubmed.ncbi.nlm.nih.gov/7185792/
- Buysse, D. J., Ancoli-Israel, S., Edinger, J. D., Lichstein, K. L., & Morin, C. M. (2006). Recommendations for a standard research assessment of insomnia. Sleep, 29(9), 1155–1173. https://doi.org/10.1093/sleep/29.9.1155
- Buysse, D. J., Reynolds, C. F., III, Monk, T. H., Berman, S. R., & Kupfer, D. J. (1989). The Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. Psychiatry Research, 28(2), 193–213. https://doi.org/10.1016/0165-1781(89)90047-4
- Czeisler, C. A., Duffy, J. F., Shanahan, T. L., Brown, E. N., Mitchell, J. F., Rimmer, D. W., Ronda, J. M., Silva, E. J., Allan, J. S., Emens, J. S., Dijk, D. J., & Kronauer, R. E. (1999). Stability, precision, and near-24-hour period of the human circadian pacemaker. Science, 284(5423), 2177–2181. https://doi.org/10.1126/science.284.5423.2177
- Dijk, D.-J., & Czeisler, C. A. (1995). Contribution of the circadian pacemaker and the sleep homeostat to sleep propensity, sleep structure, electroencephalographic slow waves, and sleep spindle activity in humans. Journal of Neuroscience, 15(5), 3526–3538. https://doi.org/10.1523/JNEUROSCI.15-05-03526.1995
- Edinger, J. D., Arnedt, J. T., Bertisch, S. M., Carney, C. E., Harrington, J. J., Lichstein, K. L., Sateia, M. J., Troxel, W. M., Zhou, E. S., Kazmi, U., Heald, J. L., & Martin, J. L. (2021). Behavioral and psychological treatments for chronic insomnia disorder in adults: An American Academy of Sleep Medicine clinical practice guideline. Journal of Clinical Sleep Medicine, 17(2), 255–262. https://doi.org/10.5664/jcsm.8986
- Edinger, J. D., Arnedt, J. T., Bertisch, S. M., Carney, C. E., Harrington, J. J., Lichstein, K. L., Sateia, M. J., Troxel, W. M., Zhou, E. S., Kazmi, U., Heald, J. L., & Martin, J. L. (2021). Behavioral and psychological treatments for chronic insomnia disorder in adults: An American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment. Journal of Clinical Sleep Medicine, 17(2), 263–298. https://doi.org/10.5664/jcsm.8988
- Espie, C. A., Emsley, R., Kyle, S. D., Gordon, C., Drake, C. L., Siriwardena, A. N., Cape, J., Ong, J. C., Sheaves, B., Foster, R., Freeman, D., Costa-Font, J., Marsden, A., & Luik, A. I. (2019). Effect of digital cognitive behavioral therapy for insomnia on health, psychological well-being, and sleep-related quality of life: A randomized clinical trial. JAMA Psychiatry, 76(1), 21–30. https://doi.org/10.1001/jamapsychiatry.2018.2745
- Ford, D. E., & Kamerow, D. B. (1989). Epidemiologic study of sleep disturbances and psychiatric disorders: An opportunity for prevention? JAMA, 262(11), 1479–1484. https://doi.org/10.1001/jama.262.11.1479
- Frank, E., Kupfer, D. J., Thase, M. E., Mallinger, A. G., Swartz, H. A., Fagiolini, A. M., Grochocinski, V., Houck, P., Scott, J., Thompson, W., & Monk, T. (2005). Two-year outcomes for interpersonal and social rhythm therapy in individuals with bipolar I disorder. Archives of General Psychiatry, 62(9), 996–1004. https://doi.org/10.1001/archpsyc.62.9.996
- Freeman, D., Sheaves, B., Goodwin, G. M., Yu, L.-M., Nickless, A., Harrison, P. J., Emsley, R., Luik, A. I., Foster, R. G., Wadekar, V., Hinds, C., Gumley, A., Jones, R., Lightman, S., Jones, S., Bentall, R., Kinderman, P., Rowse, G., Brugha, T., ... Espie, C. A. (2017). The effects of improving sleep on mental health (OASIS): A randomised controlled trial with mediation analysis. The Lancet Psychiatry, 4(10), 749–758. https://doi.org/10.1016/S2215-0366(17)30328-0
- Harris, L. M., Huang, X., Linthicum, K. P., Bryen, C. P., & Ribeiro, J. D. (2020). Sleep disturbances as risk factors for suicidal thoughts and behaviours: A meta-analysis of longitudinal studies. Scientific Reports, 10, Article 13888. https://doi.org/10.1038/s41598-020-70866-6
- Harvey, A. G. (2002). A cognitive model of insomnia. Behaviour Research and Therapy, 40(8), 869–893. https://doi.org/10.1016/S0005-7967(01)00061-4
- Harvey, A. G. (2008). Sleep and circadian rhythms in bipolar disorder: Seeking synchrony, harmony, and regulation. American Journal of Psychiatry, 165(7), 820–829. https://doi.org/10.1176/appi.ajp.2008.08010098
- Howell, M., Avidan, A. Y., Foldvary-Schaefer, N., Malkani, R. G., During, E. H., Roland, J. P., McCarter, S. J., Zak, R. S., Carandang, G., Kazmi, U., & Ramar, K. (2023). Management of REM sleep behavior disorder: An American Academy of Sleep Medicine clinical practice guideline. Journal of Clinical Sleep Medicine, 19(4), 759–768. https://doi.org/10.5664/jcsm.10424
- Johns, M. W. (1991). A new method for measuring daytime sleepiness: The Epworth sleepiness scale. Sleep, 14(6), 540–545. https://doi.org/10.1093/sleep/14.6.540
- Kapur, V. K., Auckley, D. H., Chowdhuri, S., Kuhlmann, D. C., Mehra, R., Ramar, K., & Harrod, C. G. (2017). Clinical practice guideline for diagnostic testing for adult obstructive sleep apnea. Journal of Clinical Sleep Medicine, 13(3), 479–504. https://doi.org/10.5664/jcsm.6506
- Krahn, L. E., Arand, D. L., Avidan, A. Y., Davila, D. G., DeBassio, W. A., Ruoff, C. M., & Harrod, C. G. (2021). Recommended protocols for the Multiple Sleep Latency Test and Maintenance of Wakefulness Test in adults: Guidance from the American Academy of Sleep Medicine. Journal of Clinical Sleep Medicine, 17(12), 2489–2498. https://doi.org/10.5664/jcsm.9620
- Lin, L., Faraco, J., Li, R., Kadotani, H., Rogers, W., Lin, X., Qiu, X., de Jong, P. J., Nishino, S., & Mignot, E. (1999). The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell, 98(3), 365–376. https://doi.org/10.1016/S0092-8674(00)81965-0
- Lu, M., Zhang, Y., Zhang, J., Huang, S., Huang, F., Wang, T., Wu, F., Mao, H., & Huang, Z. (2023). Comparative effectiveness of digital cognitive behavioral therapy vs medication therapy among patients with insomnia. JAMA Network Open, 6(4), Article e237597. https://doi.org/10.1001/jamanetworkopen.2023.7597
- Maski, K. P., Amos, L. B., Carter, J. C., Koch, E. E., Kazmi, U., & Rosen, C. L. (2024). Recommended protocols for the Multiple Sleep Latency Test and Maintenance of Wakefulness Test in children: Guidance from the American Academy of Sleep Medicine. Journal of Clinical Sleep Medicine, 20(4), 631–641. https://doi.org/10.5664/jcsm.10974
- Maski, K., Trotti, L. M., Kotagal, S., Auger, R. R., Rowley, J. A., Hashmi, S. D., & Watson, N. F. (2021). Treatment of central disorders of hypersomnolence: An American Academy of Sleep Medicine clinical practice guideline. Journal of Clinical Sleep Medicine, 17(9), 1881–1893. https://doi.org/10.5664/jcsm.9328
- Morin, C. M., Vallières, A., Guay, B., Ivers, H., Savard, J., Mérette, C., Bastien, C., & Baillargeon, L. (2009). Cognitive behavioral therapy, singly and combined with medication, for persistent insomnia: A randomized controlled trial. JAMA, 301(19), 2005–2015. https://doi.org/10.1001/jama.2009.682
- National Institute for Health and Care Excellence. (2021). Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s (NG202). NICE guideline. https://www.nice.org.uk/guidance/NG202/chapter/1-obstructive-sleep-apnoeahypopnoea-syndrome
- National Library of Medicine. (2026, February 26). QUVIVIQ (daridorexant) tablets, U.S. prescription labeling. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3a2d1503-b816-40c9-9fac-7e03c5a3bcef
- Palagini, L., Cipriani, E., Caruso, V., Sharma, V., Gemignani, A., Bramante, A., Miniati, M., & Riemann, D. (2023). Insomnia during the perinatal period and its association with maternal and infant psychopathology: A systematic review and meta-analysis. Current Psychiatry Reports, 25(11), 617–641. https://doi.org/10.1007/s11920-023-01463-3
- Patil, S. P., Ayappa, I. A., Caples, S. M., Kimoff, R. J., Patel, S. R., & Harrod, C. G. (2019). Treatment of adult obstructive sleep apnea with positive airway pressure: An American Academy of Sleep Medicine clinical practice guideline. Journal of Clinical Sleep Medicine, 15(2), 335–343. https://doi.org/10.5664/jcsm.7640
- Peppard, P. E., Young, T., Barnet, J. H., Palta, M., Hagen, E. W., & Hla, K. M. (2013). Increased prevalence of sleep-disordered breathing in adults. American Journal of Epidemiology, 177(9), 1006–1014. https://doi.org/10.1093/aje/kws342
- Riemann, D., Spiegelhalder, K., Feige, B., Voderholzer, U., Berger, M., Perlis, M., & Nissen, C. (2010). The hyperarousal model of insomnia: A review of the concept and its evidence. Sleep Medicine Reviews, 14(1), 19–31. https://doi.org/10.1016/j.smrv.2009.04.002
- Saper, C. B., Scammell, T. E., & Lu, J. (2005). Hypothalamic regulation of sleep and circadian rhythms. Nature, 437, 1257–1263. https://doi.org/10.1038/nature04284
- Sateia, M. J., Buysse, D. J., Krystal, A. D., Neubauer, D. N., & Heald, J. L. (2017). Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: An American Academy of Sleep Medicine clinical practice guideline. Journal of Clinical Sleep Medicine, 13(2), 307–349. https://doi.org/10.5664/jcsm.6470
- Spielman, A. J., Caruso, L. S., & Glovinsky, P. B. (1987). A behavioral perspective on insomnia treatment. Psychiatric Clinics of North America, 10(4), 541–553. https://pubmed.ncbi.nlm.nih.gov/3332317/
- Thannickal, T. C., Moore, R. Y., Nienhuis, R., Ramanathan, L., Gulyani, S., Aldrich, M., Cornford, M., & Siegel, J. M. (2000). Reduced number of hypocretin neurons in human narcolepsy. Neuron, 27(3), 469–474. https://doi.org/10.1016/S0896-6273(00)00058-1
- U.S. Department of Veterans Affairs & U.S. Department of Defense. (2025). VA/DoD clinical practice guideline for the management of chronic insomnia disorder and obstructive sleep apnea. https://www.healthquality.va.gov/guidelines/CD/insomnia/index.asp
- U.S. Food and Drug Administration. (2019, April 30). Certain prescription insomnia medicines: New boxed warning due to risk of serious injuries caused by complex sleep behaviors. FDA Drug Safety Communication. https://www.fda.gov/safety/medical-product-safety-information/certain-prescription-insomnia-medicines-new-boxed-warning-due-risk-serious-injuries-caused
- Van Dongen, H. P. A., Maislin, G., Mullington, J. M., & Dinges, D. F. (2003). The cumulative cost of additional wakefulness: Dose-response effects on neurobehavioral functions and sleep physiology from chronic sleep restriction and total sleep deprivation. Sleep, 26(2), 117–126. https://doi.org/10.1093/sleep/26.2.117
- Winkelman, J. W., Berkowski, J. A., DelRosso, L. M., Koo, B. B., Scharf, M. T., Sharon, D., Zak, R. S., Kazmi, U., Falck-Ytter, Y., Shelgikar, A. V., Trotti, L. M., & Walters, A. S. (2025). Treatment of restless legs syndrome and periodic limb movement disorder: An American Academy of Sleep Medicine clinical practice guideline. Journal of Clinical Sleep Medicine, 21(1), 137–152. https://doi.org/10.5664/jcsm.11390